Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (141-150 of 252) with videos related to

Pageof 26
Sort By:
Inflammatory Bowel Diseases|January 15, 2014
Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysisAmelie Carla Moreau, Stephane Paul, Emilie Del Tedesco, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2023
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective studyMathurin Fumery, Stéphane Nancey, Jérôme Filippi, et al.
Cell Reports|November 17, 2021
Essential role of TOSO/FAIM3 in intestinal IgM reverse transcytosisNicolas Rochereau, Eva Michaud, Louis Waeckel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2013
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesXavier Roblin, Hubert Marotte, Melanie Rinaudo, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
International Journal of Colorectal Disease|April 17, 2020
Infliximab levels and antibodies in IBD-related peripheral arthralgiaAsaf Levartovsky, Bella Ungar, Miri Yavzori, et al.
Inflammatory Bowel Diseases|November 10, 2010
Adherence to adalimumab therapy in Crohn's disease: a French multicenter experienceVincent Billioud, David Laharie, Jérôme Filippi, et al.
Journal of Clinical Medicine|May 27, 2023
Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel DiseaseXavier Roblin, Gérard Duru, Konstantinos Papamichael, et al.
Inflammatory Bowel Diseases|September 10, 2013
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective studyStephane Paul, Emilie Del Tedesco, Hubert Marotte, et al.
Inflammatory Bowel Diseases|September 26, 2017
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational StudyXavier Roblin, Gilles Boschetti, Gérard Duru, et al.
Pageof 26

Showing results (141-150 of 252) with videos related to

Sort By:
Pageof 26
Inflammatory Bowel Diseases|January 15, 2014
Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysisAmelie Carla Moreau, Stephane Paul, Emilie Del Tedesco, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2023
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective studyMathurin Fumery, Stéphane Nancey, Jérôme Filippi, et al.
Cell Reports|November 17, 2021
Essential role of TOSO/FAIM3 in intestinal IgM reverse transcytosisNicolas Rochereau, Eva Michaud, Louis Waeckel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2013
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesXavier Roblin, Hubert Marotte, Melanie Rinaudo, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
International Journal of Colorectal Disease|April 17, 2020
Infliximab levels and antibodies in IBD-related peripheral arthralgiaAsaf Levartovsky, Bella Ungar, Miri Yavzori, et al.
Inflammatory Bowel Diseases|November 10, 2010
Adherence to adalimumab therapy in Crohn's disease: a French multicenter experienceVincent Billioud, David Laharie, Jérôme Filippi, et al.
Journal of Clinical Medicine|May 27, 2023
Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel DiseaseXavier Roblin, Gérard Duru, Konstantinos Papamichael, et al.
Inflammatory Bowel Diseases|September 10, 2013
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective studyStephane Paul, Emilie Del Tedesco, Hubert Marotte, et al.
Inflammatory Bowel Diseases|September 26, 2017
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational StudyXavier Roblin, Gilles Boschetti, Gérard Duru, et al.
Pageof 26